 |
97 Diseases |  |
247 Trials |
|
247 Trials |  |
14602 News |  |
| «12...140141142143144145146147148149150...170171» |
- Comparative Effectiveness and Safety of Oral Anticoagulants across Baseline Kidney Function (Best of Specialty Conferences, Science and Technology Hall) - Aug 21, 2019 - Abstract #AHA2019AHA_5330;
In practice, relative to warfarin, NOACs are progressively less commonly used with increasing degree of renal dysfunction. However, each NOAC was consistently associated with at least equivalent effectiveness and safety compared with warfarin across the range of kidney function.
- Xarelto (rivaroxaban) / Bayer, J&J, aspirin / Generic Mfg.
Large Aortic Arch Plaques are Associated With CHADS 2 and CHA 2 DS 2 -VASc Scores: A Multicenter Registry Analysis (Best of Specialty Conferences, Science and Technology Hall) - Aug 21, 2019 - Abstract #AHA2019AHA_5169;
Frequency of aortic arch plaques ≥ 4mm were significantly increased in correlation with the increases in CHADS 2 score (19%, 0 points; 33%, 1; 40%, 2; 49%, 3; 59%, 4 to 6, P <0.001, respectively), and CHA 2 DS 2 -VASc score (12%, 0 points; 19%, 1; 35%, 2; 39%, 3; 46%, 4; 55%, 5 to 8, P <0.001, respectively). On multiple logistic regression analysis, aortic arch plaques ≥ 4mm were independently associated with CHADS 2 score ≥ 2 points (odds ratio, 1.79; 95% confidence interval, 1.25-2.57; P =0.002) and CHA 2 DS 2 -VASc score ≥ 2 points (odds ratio, 3.04; 95% confidence interval, 1.77-5.24; P <0.001).
- Physician Preferences for Oral Anti-coagulation for Obese & Non-obese Patients With Non-valvular Atrial Fibrillation (Zone 3, Science and Technology Hall) - Aug 21, 2019 - Abstract #AHA2019AHA_5031;
Although DOACs were preferred across obese & non-obese patients, preference for warfarin, aspirin & others increased with increasing BMI. Overall, patients' BMI seems to be a determinant of treatment preference, but reasons for preferring an anticoagulant are fairly consistent.
- Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
Oral Anticoagulation Therapy in Patients Hospitalized With Non-Valvular Atrial Fibrillation: A Nationwide Cohort Study (Zone 3, Science and Technology Hall) - Aug 21, 2019 - Abstract #AHA2019AHA_5024;
Since the introduction of DOACs, the proportion of patients hospitalized in Scotland with NVAF who were treated with oral anticoagulation therapy has increased by a third. Compared with VKAs, DOACs were associated with a similar risk of major adverse cardiovascular events, lower risk of mortality and a trend towards lower risk of bleeding.
- Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
EVALUATION OF NOVEL ORAL ANTICOAGULANT PRESCRIPTION PATTERNS IN A TERTIARY CARE CLINIC (Zone 2, Science and Technology Hall) - Aug 21, 2019 - Abstract #AHA2019AHA_4618;
Age greater than 80 appears to be the main reason for undertreatment. This pattern is not driven by objectively higher risk of bleeding according to the patient's HAS-BLED score.
- Does 3 Weeks of Anticoagulation With a Novel Oral Anticoagulant Obviate the Need for Transesophageal Echocardiography Before Cardioversion? (Zone 2, Science and Technology Hall) - Aug 21, 2019 - Abstract #AHA2019AHA_4617;
Screening TEE is not necessary if patients have been complaint with NOAC therapy for 3 or more weeks prior to DCCV of AF or AFL. Future studies are needed to determine the safety of this strategy in patients on dose-adjusted regimens.
- Common Drug Interactions of Direct Oral Anticoagulants and Their Impact on Clinical Outcomes in Atrial Fibrillation (Zone 3, Science and Technology Hall) - Aug 21, 2019 - Abstract #AHA2019AHA_4275;
DOAC dose is often lower than recommended in these patients. Co-prescription of DOACs and these drugs is not associated with increased risk of adverse embolic and bleeding outcomes in our cohort.
- Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion With the Watchman Device (Zone 2, Science and Technology Hall) - Aug 21, 2019 - Abstract #AHA2019AHA_3167;
All regimens involving DAPT appeared to be comparable regardless of duration but a longer course of AC appears to be associated with low incidence of bleeding and stroke. These data deserve further investigation at a larger scale.
- warfarin / Generic Mfg.
Reduced Dose Direct Oral Anticoagulants Compared to Warfarin With High Time in Therapeutic Range in Nonvalvular Atrial Fibrillation (202AB) - Aug 21, 2019 - Abstract #AHA2019AHA_3072;
In this large real-world NVAF cohort, comparison of treatment with reduced dose DOACs or high TTR warfarin show a clinically significant effectiveness and safety profile in favor of DOACs. In frail NVAF patients, reduced dose DOAC treatment is preferred.
- Safety of Radiofrequency Ablation Without Pre-Procedural Trans-Esophageal Echocardiography in Patients With Atrial Fibrillation on Novel Oral Anticoagulants (Zone 2, Science and Technology Hall) - Aug 21, 2019 - Abstract #AHA2019AHA_2624;
All were on DOACs (439 Rivaroxaban, 401 Dabigatran, 390 Apixaban, and 1 Edoxaban). For patients on uninterrupted DOAC who present for ablation in AF/AFL, the procedures could be performed without TEE screening or ICE imaging of the appendage; without increased risk of complications compared to historical controls.
- | rivaroxaban / Generic mfg.
Journal: Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome. (Pubmed Central) - Aug 21, 2019
P3
Rivaroxaban therapy at an oral dose of 2.5 mg twice daily in patients treated with aspirin and clopidogrel is associated with a net reduction in fatal or irreversible events. (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction [ATLAS ACS 2-TIMI 51]; NCT00809965).
- | Xarelto (rivaroxaban) / Bayer, J&J
Clinical, Journal: Global Prospective Safety Analysis of Rivaroxaban. (Pubmed Central) - Aug 21, 2019
P=N/A
Results were broadly consistent across regions. (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation [XANTUS]; NCT01606995; Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latin America and EMEA Region [XANTUS-EL]; NCT01800006; and Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia [XANAP]; NCT01750788).
- | rivaroxaban / Generic mfg.
Biomarker, Clinical, Journal: D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy). (Pubmed Central) - Aug 21, 2019
Rivaroxaban administration lowered D-dimer levels compared wth placebo after administration of the first dose of study drug (p = 0.026), at day 30 (p < 0.001) and day 180 (p < 0.001). In conclusion, elevated baseline D-dimer was associated with an increased risk of the composite outcome within 6 months of the ACS event and administration of the Factor Xa inhibitor rivaroxaban was associated with lower D-dimer levels compared with placebo after the first dose, at day 30 and day 180.
- | Xarelto (rivaroxaban) / Bayer, J&J, aspirin / Generic Mfg.
Journal: Anticoagulation in Atherosclerotic Disease. (Pubmed Central) - Aug 21, 2019
...However, the only available therapy so far in the primary and secondary prevention of stable patients is the platelet inhibitors aspirin and clopidogrel...The addition of 2 × 2.5 mg rivaroxaban to long-term aspirin therapy not only prevented cardiovascular death, myocardial infarction and stroke, but even reduced all-cause mortality by a relative 18% after a mean follow-up of 23 months...Interestingly, however, there was no increase in fatal or intracranial haemorrhages. Therefore, a new standard therapy for high-risk patients with atherosclerotic disease may become available in the near future.
- | tacrolimus / Generic Mfg.
Review, Journal: Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy. (Pubmed Central) - Aug 21, 2019
The sparsity of data together with the lack of well-designed prospective studies of DOAC use in solid organ transplant recipients presents a unique challenge to clinicians in determining the clinical relevance of possible drug interactions. Existing evidence suggests that with attention to concomitant drug use and renal function, the co-administration of DOACs and calcineurin inhibitors is safe and effective.
- | Xarelto (rivaroxaban) / Bayer, J&J
Journal: Role of rivaroxaban in the prevention of atherosclerotic events. (Pubmed Central) - Aug 21, 2019
Preclinical data strongly suggest that rivaroxaban exerts vascular protection through different mechanisms, including improvement of endothelial functionality and fibrinolytic activity at endothelium, anti-inflammatory properties, and platelet-dependent thrombin generation. All these data indicate that among patients with atherosclerotic vascular disease, the addition of rivaroxaban 2.5 mg may provide further vascular protection.
- | rivaroxaban / Generic mfg.
Trial completion date, Trial primary completion date: Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification (clinicaltrials.gov) - Aug 21, 2019
P4, N=192, Active, not recruiting, Sponsor: RWTH Aachen University
All these data indicate that among patients with atherosclerotic vascular disease, the addition of rivaroxaban 2.5 mg may provide further vascular protection. Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Mar 2019 --> Mar 2020
- || Xarelto (rivaroxaban) / Bayer, J&J
@Bayer pra que serve o desconto do laboratório? O da farmácia é muito maior... #xarelto #remediocaro (Twitter) - Aug 20, 2019
- || Xarelto (rivaroxaban) / Bayer, J&J, Nexavar (sorafenib) / Bayer, Amgen
Indian High Court rules against @Bayer on Nexavar and Xarelto API exports https://t.co/1YlBESRXLo #pharma @BayerPharma (Twitter) - Aug 19, 2019
- THE EFFECT OF ANTICOAGULANT THERAPY ON POST ENDOSCOPIC SUBMUCOSAL DISSECTION BLEEDING FOR GASTRIC CANCER: A PROPENSITY SCORE MATCHING ANALYSIS (E-Poster Terminal 4) - Aug 18, 2019 - Abstract #UEGW2019UEGW_3843;
Anticoagulant therapy and resected specimen size were risk factors associated with post-ESD bleeding for EGC. Strategies for the prevention of post-ESD bleeding should be seriously considered for patients under anticoagulant medication.
- Xarelto (rivaroxaban) / Bayer, J&J, aspirin / Generic Mfg., warfarin / Generic Mfg.
THE SAFETY OF COLD SNARE POLYPECTOMY FOR PATIENTS ON ANTITHROMBOTIC THERAPY (A1) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2958;
Thus, CSP can be performed with a high level of safety, even in patients receiving antithrombotic agents. In addition, there were no significant differences of rates of DPPB between the continuation group and the interruption group.
- OUTCOMES OF UPPER GASTROINTESTINAL BLEEDING ARE SIMILAR BETWEEN DIRECT ORAL ANTICOAGULANTS AND VITAMIN K ANTAGONISTS: A SUB-GROUP ANALYSIS OF A FRENCH PROSPECTIVE MULTICENTER STUDY (B2) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2901;
DOACs do not alter outcomes of UGIB as compared to VKA. Comorbidities and associated treatment seem to be the most important factors worsening prognosis of UGIB.
- DELAYED BLEEDING AFTER COLONOSCOPIC TREATMENT IN PATIENTS TAKING ANTICOAGULANTS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2313;
In DOACs, the possibility of rapid onset of anticoagulant effect after oral administration was considered. We have previously reported that there was less delayed bleeding rate after gastric ESD in patients taking dabigatran.
- THE EFFECT OF ANTICOAGULANT THERAPY ON POST ENDOSCOPIC SUBMUCOSAL DISSECTION BLEEDING FOR GASTRIC CANCER: A PROPENSITY SCORE MATCHING ANALYSIS (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1873;
Anticoagulant therapy and resected specimen size were risk factors associated with post-ESD bleeding for EGC. Strategies for the prevention of post-ESD bleeding should be seriously considered for patients under anticoagulant medication.
- PROSPECTIVE EVALUATION OF GASTROINTESTINAL BLEEDING IN PATIENTS UNDER DIRECT ORAL ANTICOAGULANT THERAPY: A REAL-WORLD STUDY (Poster Exhibition - Hall 7) - Aug 18, 2019 - Abstract #UEGW2019UEGW_1719;
Gastrointestinal bleeding severity is similar in patients taking DOACs when compared to patients under VKAs therapy. Future studies with a higher number of patients are needed to confirm our data.
- | Xarelto (rivaroxaban) / Bayer, J&J, warfarin / Generic Mfg.
Journal: Effect of different types of anticoagulants in the prevention of venous thrombosis in the operation of knee joint bone operation. (Pubmed Central) - Aug 17, 2019
It has been proved that LMWH has good efficacy and safety in the prevention of VTE after hip and knee arthroplasty and is a priority anticoagulant. Rivaroxaban can effectively control the occurrence of DVT and the drug is convenient, but it will increase the risk of bleeding and should be used carefully.
- | Xarelto (rivaroxaban) / Bayer, J&J
Journal: Anticoagulant effects of Rivaroxaban after surgical fixation of spinal fracture. (Pubmed Central) - Aug 17, 2019
It significantly reduced the incidence of VTE after spinal fracture and nerve injury, and did not increase the risk of bleeding. It is an ideal type of prophylactic anticoagulant after the operation of spinal fracture, which is worthy of further clinical study.
- | Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
Clinical, Journal: Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation. (Pubmed Central) - Aug 17, 2019
It is an ideal type of prophylactic anticoagulant after the operation of spinal fracture, which is worthy of further clinical study. No significant risk differences of MI were found in the direct comparisons of DOACs, and DOACs were all associated with a significant risk reduction of MI compared with VKA.
- | Xarelto (rivaroxaban) / Bayer, J&J
Journal: In embolic stroke of undetermined source, rivaroxaban vs aspirin did not reduce recurrence and increased bleeding. (Pubmed Central) - Aug 17, 2019
No significant risk differences of MI were found in the direct comparisons of DOACs, and DOACs were all associated with a significant risk reduction of MI compared with VKA. No abstract available
- | fondaparinux / Generic Mfg.
Journal: Initial and Long-Term Treatment of Pulmonary Embolism: Current Approach and Future Perspectives. (Pubmed Central) - Aug 17, 2019
Beyond this period, an individual re-evaluation of the risk-to-benefit ratio of anticoagulation should be performed, based on several factors, including the type of index event, age, sex, D-dimer and residual venous obstruction. Possibly safer strategies can be offered to higher risk patients requiring extended duration of treatment, including the DOACs apixaban and rivaroxaban at reduced dose.
- | Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
Journal: Direct Oral Anticoagulants and Myocardial Infarction: The Dust Is Settling. (Pubmed Central) - Aug 17, 2019
Possibly safer strategies can be offered to higher risk patients requiring extended duration of treatment, including the DOACs apixaban and rivaroxaban at reduced dose. No abstract available
- | Xarelto (rivaroxaban) / Bayer, J&J
Journal: Ischemia and Bleeding on the Horns of a Dilemma: Do Only Hard Endpoints Count? (Pubmed Central) - Aug 17, 2019
No abstract available No abstract available
- | Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim
Clinical, Journal: Routine Coagulation Tests in Patients With Nonvalvular Atrial Fibrillation Under Dabigatran and Rivaroxaban Therapy: An Affordable and Reliable Strategy? (Pubmed Central) - Aug 16, 2019
The routine coagulation tests were able to identify out of therapeutic range concentrations for dabigatran and rivaroxaban. We suggest the use of these screening tests to better understand and monitor the subtherapeutic concentrations of these DOACs.
- | Xarelto (rivaroxaban) / Bayer, J&J, aspirin / Generic Mfg., Eliquis (apixaban) / BMS
Clinical, Journal: Implementation and Validation of the 2013 Caprini Score for Risk Stratification of Arthroplasty Patients in the Prevention of Venous Thrombosis. (Pubmed Central) - Aug 16, 2019
The 2013 version of the Caprini RAM retrospectively stratified 7 of the 8 VTE events correctly, while only 1 VTE was identified with the prospective department protocol. This tool provided a consistent, accurate, and efficacious method for risk stratification and selection of chemoprophylaxis.
- | Xarelto (rivaroxaban) / Bayer, J&J
Clinical, Journal: Venous thromboembolic complications in oncological patients: present-day possibilities of effective and safe anticoagulant therapy (Pubmed Central) - Aug 16, 2019
There are also findings obtained in a separate randomized study, confirming efficacy and safety of rivaroxaban in treatment of patients with cancer-associated venous thromboembolic complications as compared with therapy with low-molecular-weight heparins. Namely these results formed the basis for the guidelines of the International Society on Thrombosis and Hemostasis (SSC ISTH), according to which rivaroxaban may be regarded as an alternative to low-molecular-weight heparins in certain clinical situations.
- | Xarelto (rivaroxaban) / Bayer, J&J
Preclinical, Journal, IO Biomarker: Protective effect of rivaroxaban on arteriosclerosis obliterans in rats through modulation of the toll-like receptor 4/NF-κB signaling pathway. (Pubmed Central) - Aug 16, 2019
Rats in the Riv group had reduced expression of toll-like receptor 4 (TLR4), NF-κB and MCP-1, and increased expression of TGF-β in femoral artery tissues compared with the model group. Therefore rivaroxaban may have exerted its anti-atherosclerotic effects by regulating the expression of genes in the TLR4/NF-κB signaling pathway and the activation of the downstream molecules.
- | Xarelto (rivaroxaban) / Bayer, J&J, Cardilor (amiodarone) / Generic Mfg.
Retrospective data, Journal: Secondary Prevention of Nonvalvular Atrial Fibrillation: A Retrospective Cohort Study. (Pubmed Central) - Aug 16, 2019
On the contrary, the amiodarone use has been associated with a decreased risk of AF recurrences and hospital admissions. Thus, amiodarone might be an efficacious tool for realizing a successful long-term AF secondary prevention.
- ||| Xarelto (rivaroxaban) / Bayer, J&J
Interview: In another interview segment with @DLBHATTMD, the Harvard professor explains rivaroxaban's benefit for PAD/CAD. https://t.co/zYGfmsiPJs (Twitter) - Aug 16, 2019
- ||| Xarelto (rivaroxaban) / Bayer, J&J, Eliquis (apixaban) / BMS
Retrospective data, Review, Real-World Evidence: Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world https://t.co/LNxxKDeinG (Twitter) - Aug 16, 2019
- | rivaroxaban / Generic mfg., aspirin / Generic mfg.
Biomarker, New P4 trial: Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy (clinicaltrials.gov) - Aug 15, 2019
P4, N=30, Not yet recruiting, Sponsor: LifeBridge Health
- | Clinical, Journal: Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants. (Pubmed Central) - Aug 15, 2019
Although prior studies have shown a higher frequency of gastrointestinal bleeding in patients treated with DOACs compared to warfarin, our data suggest that gastrointestinal bleeding in patients taking DOACs may be less severe. These differences occurred despite significantly greater concomitant aspirin use in the DOAC group compared to warfarin users.
- | Xarelto (rivaroxaban) / Bayer, J&J
Clinical, Observational data, Journal: Rivaroxaban for thrombosis prophylaxis in extensive hip and knee operations. Subanalysis of the German cohort (XAMOS-DE) of non-interventional study XAMOS (Pubmed Central) - Aug 15, 2019
These differences occurred despite significantly greater concomitant aspirin use in the DOAC group compared to warfarin users. The results from XAMOS-DE confirm in clinical practice the favorable benefit-risk ratio of rivaroxaban, as well as the current S3 guidelines for thromboembolism prophylaxis with rivaroxaban in elective hip and knee replacement.
- | Xarelto (rivaroxaban) / Bayer, J&J
Clinical, Journal: Usefulness and Safety of Rivaroxaban in Patients Following Isolated Mitral Valve Replacement With a Mechanical Prosthesis. (Pubmed Central) - Aug 15, 2019
P=N/A
Mean and peak pressure gradients, peak velocity, effective orifice area, and PHT were similar before and after the intervention. In conclusion, the use of rivaroxaban for 90 days in seven patients after replacement of mitral valve with the mechanical prosthesis did not present thromboembolic or bleeding events (NCT02894307).
- | Xarelto (rivaroxaban) / Bayer, J&J
Journal: Rivaroxaban for post-discharge thromboprophylaxis: the MARINER trial. (Pubmed Central) - Aug 15, 2019
In conclusion, the use of rivaroxaban for 90 days in seven patients after replacement of mitral valve with the mechanical prosthesis did not present thromboembolic or bleeding events (NCT02894307). No abstract available
- | Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
Retrospective data, Journal: Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. (Pubmed Central) - Aug 15, 2019
DOAC concentrations are often low in the presence of EIDs. DOAC concentration monitoring may be useful in settings requiring both DOAC and EIDs.
- | Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
Clinical, Journal: Direct oral anticoagulants vs non-vitamin K antagonist in atrial fibrillation: A prospective, propensity score adjusted cohort study. (Pubmed Central) - Aug 15, 2019
DOAC concentration monitoring may be useful in settings requiring both DOAC and EIDs. No abstract available
- | Clinical, Journal: Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice. (Pubmed Central) - Aug 15, 2019
No abstract available No abstract available
- | rivaroxaban / Bayer, Generic mfg.
Clinical, Journal: Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients. (Pubmed Central) - Aug 15, 2019
P1/2
Although these limited data and patient volume reached the statistical difference which was able to provide the evidence proofed to compare the potency of those two anticoagulants, it could be regarded as the preliminary data provide the clinical results for cancer patients who were placed in the condition of apheresis and subsequently undergone adoptive T cell immunotherapy.Trial registration ClinicalTrials.gov identifier, NCT03282643. Registered 16 February 2016, http://www.ClinicalTrials.gov/ NCT03282643.
- | Xarelto (rivaroxaban) / Bayer, J&J
Clinical, Journal: Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. (Pubmed Central) - Aug 15, 2019
In this large cohort of ESUS patients, several features including prior stroke or TIA, advanced age, current tobacco user, multiple acute infarcts on neuroimaging, and diabetes independently identified those with an increased risk of ischemic stroke recurrence. The relative effects of rivaroxaban and aspirin were similar across the spectrum of independent stroke predictors and recurrent stroke risk status.
- | Xarelto (rivaroxaban) / Bayer, J&J
Retrospective data, Journal: Retrospective evaluation of the efficacy and safety of rivaroxaban in patients with cancer-associated venous thromboembolism: A single-center study. (Pubmed Central) - Aug 15, 2019
Recurrence and major bleeding events on rivaroxaban were relatively low despite the fact that many patients had metastatic disease. Among 52 patient deaths (42.3%), none were due to VTE or bleeding complications; the cause of death in the majority of cases was cancer progression.Rivaroxaban is effective and safe for the treatment of cancer-associated VTE.